SAN FRANCISCO, June 18, 2025 (GLOBE NEWSWIRE) -- Did you suffer substantial losses on your Napco Security Technologies (NASDAQ: NSSC) investments? Hagens Berman reminds investors of a critical deadline: June 24, 2025. This is your deadline for seeking appointment as lead plaintiff in a federal securities class action lawsuit against Napco. If you purchased Napco securities between February 5, 2024, and February 3, 2025, inclusive, and experienced significant losses, click here. You may have legal recourse. ...

SAN DIEGO, June 18, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the "Class Period"), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI's top executives with violations of the Secur ...

Leadership Transition - Iovance Biotherapeutics Inc. announced the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025, to pursue other endeavors [1][2] - Bellemin's departure coincides with the company's struggles, including a commercial setback for its flagship drug, Amtagvi, and a class-action securities lawsuit [1][3] Commercial Performance - Iovance's first-quarter sales for Amtagvi significantly underperformed Wall Street expectations, leading to a revision of full-year revenue projections [3] - Following the disappointing results and revenue guidance revision, Iovance's stock fell over 44%, from $3.17 per share on May 8, 2025, to $1.75 per share by the close of trading on May 9, 2025 [6][7] Legal Challenges - Iovance is facing a securities fraud class action lawsuit related to the company's portrayal of its authorized treatment centers (ATCs), which are essential for Amtagvi's administration [4][5] - The lawsuit alleges discrepancies between the company's claims about ATC operations and the actual performance, including delays in patient treatment initiation and high patient drop-off rates [5][6] Market Reaction - The market reacted negatively to the company's underwhelming first-quarter results and the downward revision of revenue guidance, attributing the issues to slow treatment timelines and inefficiencies in patient selection [6][7] - Hagens Berman is investigating the allegations and scrutinizing whether Iovance's public statements aligned with internal realities [8]

Core Insights - Newmark Group, Inc. has successfully represented the United Nations in a significant long-term office lease renewal and expansion at 2 United Nations Plaza, encompassing 425,190 square feet across 26 stories [1][3] - The lease renewal consolidates the UN's operations in New York City, creating a unified headquarters and includes a two-story retail component [1][3] - The transaction is part of a broader $500 million capital improvement program by the landlord, which includes infrastructure upgrades and enhanced security features [4] Company Overview - Newmark Group, Inc. is a leading commercial real estate advisor, providing services to institutional investors, global corporations, and other property owners [1][6] - For the twelve months ending March 31, 2025, Newmark generated revenues exceeding $2.8 billion and operates from 165 offices with approximately 8,100 professionals globally [6]

Core Viewpoint - Texas Instruments plans to invest over $60 billion to expand its manufacturing capabilities in the US, marking a significant move to enhance domestic semiconductor production amid governmental pressures [1][3][6]. Investment Details - The investment will be allocated to build or expand seven chip-making facilities across three sites in Texas and Utah, including two new facilities in Sherman, Texas [3][5]. - This investment is part of a broader strategy that includes a previous commitment of at least $18 billion under the $52.7 billion CHIPS and Science bill [2][6]. - The company aims to create 60,000 jobs through this investment, which it describes as the "largest investment in foundational semiconductor manufacturing in US history" [3][5]. Competitive Landscape - Texas Instruments is focusing on in-house manufacturing to counteract competition from Chinese analog chipmakers [6][9]. - Unlike AI chip firms such as Nvidia and AMD, Texas Instruments specializes in analog chips used in everyday devices, serving a diverse client base that includes major companies like Apple, SpaceX, and Ford [7][9]. Government Relations - The investment follows a finalized government subsidy of $1.61 billion from the Biden administration to support the construction of three new facilities [2][10]. - Analysts suggest that the spending plans may be seen as gestures towards the Trump administration, which has expressed concerns over semiconductor imports and the CHIPS and Science Act [9].

Core Viewpoint - The FDA has approved Gilead's lenacapavir, a twice-yearly antiviral injection for HIV prevention, which could significantly impact global public health and help in the fight against the HIV epidemic [2][5]. Product Efficacy and Impact - Lenacapavir has shown the ability to virtually eliminate new HIV infections when administered every six months, outperforming existing daily pills and monthly injections [3][12]. - In clinical trials, the injection demonstrated a 99.9% efficacy rate, with only two infections among over 2,000 patients, proving to be 89% more effective than Gilead's daily pill Truvada [12][13]. Market Potential and Pricing - Analysts estimate lenacapavir could achieve peak sales of around $4 billion globally for both prevention and treatment [7]. - The current price for lenacapavir, under its treatment brand Sunlenca, exceeds $42,200 per year, but it could potentially be produced for as low as $26 to $40 annually [6]. Access and Distribution - Gilead plans to align the pricing of lenacapavir for HIV prevention with existing branded PrEP options, which are around $2,000 per month for daily pills [8]. - The company has licensed six generic manufacturers to produce lower-cost versions of the injection for 120 low- and lower-middle-income countries, and will supply doses for up to 2 million people at no profit before generics are available [9]. Challenges to Implementation - Proposed cuts to federal funding for HIV prevention, particularly affecting Medicaid, pose a significant threat to access for underserved populations [14][15]. - The potential reduction in funding could destabilize HIV prevention efforts and make it harder to distribute Gilead's injection effectively [16][17].

BofA Securities analyst Wamsi Mohan initiated coverage on SanDisk SNDK with a Buy rating and a price target of $61 on Wednesday.Mohan noted that SanDisk is a leading developer and manufacturer of data storage devices based on NAND flash technology.The rerating reflected: • Improving memory pricing as supply and demand have turned favorable.• Margins upside given pricing trajectory and operating leverage.• Better through-cycle economics given the mix of end markets relative to peers.• A joint venture structu ...

Core Insights - Adobe and Apple are integrating artificial intelligence (AI) into their core products, with Adobe focusing on creative tools and Apple enhancing its operating systems [2][3] - Global spending on AI technologies is projected to exceed $749 billion by 2028, with enterprises expected to contribute 67% of the $227 billion AI spending in 2025 [3] - Both companies face competition from Microsoft, Amazon, and Alphabet, with Adobe shares down 13.9% year-to-date and Apple shares down 21.8% [4] Adobe's Position - Adobe has expanded its AI offerings with products like Adobe GenStudio and Firefly Services, which facilitate collaboration on marketing campaigns [6] - The Firefly Video Model in Premiere Pro allows for instant generation and extension of video and audio clips, while the Firefly App is gaining traction for AI-powered content creation [7][11] - Adobe's Digital Media Annual Recurring Revenue (ARR) has increased by 12% year-over-year, reaching $18.09 billion [12] - The company is on track to exceed its $250 million ARR target from AI-first products by the end of fiscal 2025 [12] - Adobe's earnings estimates for fiscal 2025 have risen to $20.41 per share, indicating a 10.8% increase over the previous year [16] Apple's Position - Apple is seeing improved iPhone 16 sales in regions where Apple Intelligence features are available, with plans to expand language support for these features [13][14] - New features for Apple Intelligence include Live Translation and enhancements to visual intelligence, expected to be available this fall [14] - The consensus estimate for Apple's fiscal 2025 earnings has decreased to $7.11 per share, suggesting a 5.33% growth over fiscal 2024 [17] Valuation Comparison - Adobe is trading at a lower forward Price/Sales ratio of 6.62X compared to Apple's 7.04X, indicating a more favorable valuation for Adobe [18] - Both companies are considered overvalued, but Adobe's focus on monetization and partnerships with major firms is expected to drive growth [21] - Adobe's revenue guidance has been raised to between $23.5 billion and $23.6 billion, reflecting positive momentum [21] Investment Recommendation - Adobe is rated as a stronger buy with a Zacks Rank 2, while Apple holds a Zacks Rank 3, indicating a hold position [22]

Core Insights - Reddit (RDDT) is enhancing its advertising business by leveraging real-time community engagement to provide strategic insights for brands, gaining traction among advertisers seeking authenticity and scale [1][4]. Advertising Business Development - Reddit launched Community Intelligence, a suite that allows marketers to monitor live conversations across subreddits, analyze sentiment, and optimize campaign decisions, transforming the platform into a dynamic planning engine [2]. - In Q1 2025, Reddit's advertising revenue reached $358.6 million, a 61% increase year-over-year, with performance campaigns making up 60% of total ad spend, indicating strong growth among mid- and lower-funnel advertisers [4][10]. User Engagement Metrics - User engagement on Reddit is robust, with Weekly Active Users at 401 million and Daily Active Uniques at 108 million, both reflecting a 31% year-over-year increase, which is a key driver for advertising growth [3][10]. Competitive Landscape - Reddit faces significant competition from Alphabet (GOOGL) and Meta Platforms (META), both enhancing their AI-driven advertising capabilities. Alphabet's Google Ads and YouTube offer large-scale performance marketing, while Meta strengthens its advertising tools across its platforms [6][7]. Valuation and Market Performance - Reddit's stock has declined 18.1% year-to-date, contrasting with a 1.6% return for the broader Zacks Computer & Technology sector and a 13% increase in the Zacks Internet - Software industry [8]. - The forward 12-month Price/Sales ratio for Reddit is 11.8X, significantly higher than the sector average of 6.36X, indicating a premium valuation [12]. Earnings Estimates - The Zacks Consensus Estimate for Q2 2025 earnings is 19 cents per share, an improvement from a loss of 6 cents per share in the same quarter last year. For fiscal 2025, the earnings estimate is $1.21 per share, up from a loss of $3.33 per share in fiscal 2024 [15].

Group 1 - Alaris Equity Partners Income Trust has declared a trust distribution of $0.34 per trust unit for Q2 2025, which annualizes to $1.36 per unit [1] - The distribution is scheduled to be paid on July 15, 2025, to unitholders of record on June 30, 2025 [1] Group 2 - Alaris invests in a diversified group of private businesses primarily through structured equity, aiming to deliver stable and predictable returns to unitholders [2] - The strategy includes common equity positions to align returns with the founders of Private Company Partners [2]